Back to Search Start Over

Quantifying the risk of spillover reduction programs for human health.

Authors :
Nuismer SL
Basinski AJ
Schreiner CL
Eskew EA
Fichet-Calvet E
Remien CH
Source :
PLoS computational biology [PLoS Comput Biol] 2024 Aug 15; Vol. 20 (8), pp. e1012358. Date of Electronic Publication: 2024 Aug 15 (Print Publication: 2024).
Publication Year :
2024

Abstract

Reducing spillover of zoonotic pathogens is an appealing approach to preventing human disease and minimizing the risk of future epidemics and pandemics. Although the immediate human health benefit of reducing spillover is clear, over time, spillover reduction could lead to counterintuitive negative consequences for human health. Here, we use mathematical models and computer simulations to explore the conditions under which unanticipated consequences of spillover reduction can occur in systems where the severity of disease increases with age at infection. Our results demonstrate that, because the average age at infection increases as spillover is reduced, programs that reduce spillover can actually increase population-level disease burden if the clinical severity of infection increases sufficiently rapidly with age. If, however, immunity wanes over time and reinfection is possible, our results reveal that negative health impacts of spillover reduction become substantially less likely. When our model is parameterized using published data on Lassa virus in West Africa, it predicts that negative health outcomes are possible, but likely to be restricted to a small subset of populations where spillover is unusually intense. Together, our results suggest that adverse consequences of spillover reduction programs are unlikely but that the public health gains observed immediately after spillover reduction may fade over time as the age structure of immunity gradually re-equilibrates to a reduced force of infection.<br />Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: S.L. Nuismer is listed as an inventor on a pending patent for a Lassa virus vaccine.<br /> (Copyright: © 2024 Nuismer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Details

Language :
English
ISSN :
1553-7358
Volume :
20
Issue :
8
Database :
MEDLINE
Journal :
PLoS computational biology
Publication Type :
Academic Journal
Accession number :
39146377
Full Text :
https://doi.org/10.1371/journal.pcbi.1012358